https://ps-341inhibitor.com/co....ncanavalin-a-being-a
Cancer heterogeneity represents a possible barrier for the analysis of predicitive biomarkers. MSI has been reported in pancreatic cancer, but data regarding the possible extent of intratumoral heterogeneity are lacking. Techniques to study MSI heterogeneity in pancreatic disease, a tissue microarray (TMA) comprising 597 tumors was screened by immunohistochemistry with antibodies for the mismatch restoration (MMR) proteins MLH1, PMS2, MSH2, and MSH6. Leads to six suspiciou
Like
Comment
Share
